Were you recently prescribed the Doxycycline medication due to a tick-borne illness diagnosis? Dr. John Aucott, Director of the Johns Hopkins Lyme Disease Research Center, informs us on all we need to know about Doxycycline, an oral drug commonly used to treat Lyme Disease.
Although the prognosis after treatment of Lyme disease is generally good there are patients who remain significantly ill following standard antibiotic therapy for Lyme disease. In this fifth and final video of our series on Lyme Disease, Dr. Aucott discusses the prognosis of those with Lyme Disease.
Established in the spring of 2015, the Johns Hopkins Lyme Disease Research Center is the first research center in a major department of medicine in the United States focused on patient-based research in all aspects of Lyme disease. The mission of the Center is to understand and urgently address the varied manifestations of Lyme disease and translate our pioneering multi-disciplinary research into improved patient care, education, and health outcomes. By improving the understanding of the causes and complex biologic processes of Lyme disease, we strive for a future where more accurate diagnoses and effective treatments bring new hope to Lyme disease patients and their families.
Each year, roughly 300,000 cases of Lyme Disease are reported to the Centers for Disease Control and Prevention; it is estimated that this represents a small portion of actual cases of the Disease. Methods of diagnosis and treatment have been, for the most part, inadequate at speaking to the complex needs of these patients.